DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (

达拉斯，2026年11月12日（环球电讯社）——（

www.InvestorsTape.com

www.InvestorsTape.com

)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased

)— NeOnc Technologies Holdings（纳斯达克股票代码：NTHI）首席执行官 Amir Heshmatpour 已购入

another 70,000 shares in the open market

在公开市场上再购买70,000股

, bringing his recent purchases to

，将其最近的购买物品带至

150,000 shares

150,000股

as the company approaches important clinical and regulatory milestones.

随着公司临近重要的临床和监管里程碑。

The latest transactions represent approximately

最新交易约占

$294,500

294,500美元

, with purchases reaching

，采购额达到

$4.49 per share

每股4.49美元

. Combined with the preceding 80,000-share purchases announced by NeOnc, Heshmatpour committed approximately

结合 NeOnc 此前宣布的 80,000 股购买计划，Heshmatpour 承诺了约

$563,582 across November 5–11

11月5日至11日共计563,582美元

.

。

Our bullish interpretation: the CEO continues putting personal capital behind his conviction as NeOnc’s development story advances.

我们的看涨解读：随着 NeOnc 研发进程的推进，首席执行官继续以个人资金投入来彰显其信心。

The CEO Keeps Buying Higher

首席执行官持续高位增持

The latest filing summary details three purchases:

最新提交的摘要详细列出了三笔购买交易：

Transaction date

交易日期

Shares purchased

已购入股份

Reported price

报告价格

November 10

11月10日

50,000

五万

$4.192 weighted average

加权平均价 4.192 美元

November 11

11月11日

10,000

一万

$4.49

4.49美元

November 11

11月11日

10,000

10,000

$4.00

4.00美元

Total

总计

70,000

七万

Approximately $4.207 average

平均约4.207美元

The transactions increased Heshmatpour’s reported direct holdings to

这些交易使赫什马特普尔申报的直接持股量增加至

3,333,000 shares

3,333,000股

, separate from his indirectly held positions.

，与其间接持有的头寸相分离。

NeOnc previously announced purchases of

NeOnc 此前宣布的采购

80,000 shares across November 5, 6 and 9

11月5日、6日和9日共计80,000股

, totaling approximately

，总计约

$269,082

269,082美元

using personal funds.

使用个人资金。

The progression stands out.

进展显著。

Earlier purchases came in the low-to-mid $3 range. The CEO continued adding above $4, including a transaction at $4.49.

早期的买入价格介于3美元至3.5美元之间。首席执行官继续以高于4美元的价格增持，其中包括一笔成交价为4.49美元的交易。

These open-market purchases increase his ownership as investors evaluate the company’s next milestones. Roth MKM also recently

随着投资者评估公司的下一个里程碑，这些公开市场购买增加了他的持股。Roth MKM 最近也

reaffirmed its Buy rating and $20 price target

重申其“买入”评级及20美元的目标价

, maintaining its bullish valuation.

，维持其看涨估值。

FDA Meeting Puts Phase 3 and Accelerated Approval on the Agenda

FDA会议将III期临床试验和加速批准列入议程

On November 11, NeOnc announced that the FDA granted a

11月11日，NeOnc宣布美国食品药品监督管理局（FDA）批准了

Type B End-of-Phase meeting scheduled for early January 2027

B类阶段结束会议定于2027年1月初举行

to discuss a potential accelerated approval pathway for intranasal NEO100.

讨论NEO100鼻内给药的潜在加速审批途径。

NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for

NeOnc 拟就其临床和非临床证据是否能够支持加速批准申请征求反馈意见

recurrent or progressive IDH-mutant grade 4 astrocytoma

复发性或进展性IDH突变型4级星形细胞瘤

.

。

The company will also seek agreement on

该公司还将寻求就以下事项达成协议：

NEO100-012, a proposed randomized Phase 3 trial

NEO100-012，一项拟议的随机III期临床试验

comparing NEO100 with investigator-selected standard-of-care chemotherapy.

将 NEO100 与研究者选择的标准护理化疗进行比较。

Overall survival would be the primary endpoint

总生存期将作为主要终点

, with the study intended to provide registrational and confirmatory evidence.

，该研究旨在提供注册和确证性证据。

NeOnc now has an FDA discussion scheduled around a potential approval pathway and the design of a Phase 3 trial.

NeOnc 现已安排与美国食品药品监督管理局（FDA）就潜在的批准路径和 III 期临床试验设计进行讨论。

Positive Phase 2a findings provide the foundation for that discussion and give investors a defined next step to follow.

积极的二期a阶段研究结果为该讨论奠定了基础，并为投资者指明了明确的下一步行动方向。

Two Programs. Several Dates to Watch.

两个项目。多个值得关注的日期。

The January meeting adds to an already active calendar:

1月的会议为原本就已繁忙的日程增添了更多安排：

November 13:

11月13日：

Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation at the Society for Neuro-Oncology Annual Meeting.

更新的NEO100 1/2a期结果和NEO212 1期数据计划在神经肿瘤学会年会上进行展示。

November 17:

11月17日：

NeOnc’s FDA End-of-Phase 1 meeting for NEO212 is scheduled to address proposed Phase 2 development and next steps.

NeOnc公司针对NEO212的FDA一期结束会议计划讨论拟议的二期开发方案及后续步骤。

Early January 2027:

2027年1月上旬：

The newly announced NEO100 meeting will address its potential accelerated approval pathway and proposed Phase 3 trial.

新宣布的NEO100会议将讨论其潜在的加速审批途径和提议的第三阶段试验。

Two investigational drugs, upcoming scientific presentations, separate FDA discussions and continued CEO buying give investors several developments to watch.

两款在研药物、即将发布的科学报告、与FDA的单独讨论以及首席执行官的持续增持，为投资者提供了多个值得关注的动态。

A Larger Short Position Adds Potential Fuel

更大的空头头寸增添潜在动能

The latest short-interest update puts NTHI at approximately

最新的空头头寸更新显示，NTHI 的空头兴趣约为

921,000 shares short as of October 30

截至10月30日，做空股数为921,000股

, compared with

，与……相比

876,682 on October 15

10月15日为876,682

.

。

That represents an increase of roughly

这表示增长了大约

44,000 shares

44,000 股

before the stock’s recent advance through $4.

在该股近期突破4美元之前

Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at this week’s Society for Neuro-Oncology annual meeting.

更新后的NEO100数据和NEO212一期研究结果计划在本周的神经肿瘤学会年会上进行展示。

About InvestorsTape.com

关于 InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence..

在 InvestorsTape.com，我们的使命简单明了：提供穿透噪音的财经新闻，聚焦那些塑造未来十年增长格局的企业、创新和市场力量。在高频头条和短暂叙事主导的环境中，我们为重要故事带来清晰性、深度与平衡，帮助投资者发现高潜力公司，并自信地评估新兴机遇。

Contact

联系

benh@investorstape.com

benh@investorstape.com

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives.

本新闻稿包含适用证券法律定义下的前瞻性陈述，包括可能涉及 NeOnc Technologies Holdings 未来收入、增长轨迹、盈利前景、扩张计划、战略合作伙伴关系、潜在监管批准以及其他预测、计划和目标的陈述。

Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions.

前瞻性陈述受各种风险和不确定性的影响，可能导致实际结果与明示或暗示的结果存在重大差异，这些因素包括市场状况、场馆开业时间、执行风险、运营表现、竞争、监管事项以及整体经济状况。

Readers should not place undue reliance on these statements, which speak only as of the date made..

读者不应过度依赖这些陈述，其内容仅反映作出之日的情况。

General Disclaimer:

一般免责声明：

InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available

InvestorsTape.com 已就 NeOnc Technologies Holdings 的新闻和编辑报道获得补偿，更多披露信息可供查阅。

here

这里

. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

本通讯仅提供信息及新闻目的，反映 InvestorsTape.com 的独立编辑观点。

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice.

本社论讨论的是研究性疗法和临床试验结果，不构成医疗建议，也不构成买卖证券的建议。本出版物受美国宪法第一修正案保护的言论自由权保护。本文任何内容均不构成要约、招揽或买卖任何证券的建议，也不应被解读为投资建议。

Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision..

投资证券涉及风险，包括可能损失本金。建议读者在做出任何投资决策前，自行进行尽职调查并咨询合格的财务顾问。